PanGenetics is a therapeutic antibody company that specialises in developing antibodies from the late preclinical stage through to clinical proof of concept. The company has built up a portfolio of antibody drugs through in-licensing and employs a lean business model with most development activities outsourced. The most advanced programs of PanGenetics are PG102, a CD40 antagonist that has already shown promise in an open label Crohn's study, and PG110, a Nerve Growth Factor agonist for the use in chronic pain.

Speaker Profile

Arnoud Dijkstra PhD, Chief Business Officer

Before joining Pangenetics, Arnoud Dijkstra spent 14 years in the Swiss pharmaceutical and biotech industry.  Having received his Ph.D. in Biochemistry from the University of Groningen, the Netherlands, Arnoud joined the Research Department of Hoffmann-La Roche in Basel in 1992, where he spent eight years in several management positions. After this experience he switched to biotech and was involved in setting up the Basel branch of Morphochem, as VP of Operations.  He then joined Actelion Pharmaceuticals where he served as Director of Business Development and was responsible for all in-licensing Search & Evaluation. In addition he was involved in Actelion's Investor Relations activities.